Zum Hauptinhalt springen
UB Siegen

PACAP regulates VPAC1 expression, inflammatory processes and lipid homeostasis in M1- and M2-macrophages.

Witzel, R ; Block, A ; et al.
In: Frontiers in cardiovascular medicine, Jg. 10 (2023-10-13), S. 1264901
Online academicJournal
Zugriff:
Zum Volltext

Background: Pituitary adenylate cyclase-activating polypeptide (PACAP) acts as an anti-atherogenic neuropeptide and plays an important role in cytoprotective, as well as inflammatory processes, and cardiovascular regulation. Therefore, the aim of this study is to investigate the regulatory effects of PACAP and its receptor VPAC1 in relation to inflammatory processes and lipid homeostasis in different macrophage (MΦ) subtypes.

Methods: To investigate the role of PACAP deficiency in the pathogenesis of atherosclerosis under standard chow (SC) or cholesterol-enriched diet (CED) in vivo , PACAP -/- mice were crossbred with ApoE -/- to generate PACAP -/- /ApoE -/- mice. Lumen stenosis in the aortic arch and different MΦ-subtypes were analyzed in atherosclerotic plaques by quantitative immunohistochemistry. Undifferentiated bone marrow-derived cells (BMDC) from 30-weeks-old ApoE -/- and PACAP -/- /ApoE -/- mice were isolated, differentiated into BMDM1- and BMDM2-MΦ, and incubated with oxidized low-density lipoprotein (oxLDL). In addition, PMA-differentiated human THP-1 MΦ were further differentiated into M1-/M2-MΦ and subsequently treated with PACAP38, the VPAC1 agonist [(Ala11,22,28)VIP], the antagonist (PG 97-269), and/or oxLDL. Uptake/accumulation of oxLDL was analyzed by oxLDL-DyLight™488 and Bodipy™ 493/503. The mRNA expression was analyzed by qRT-PCR, protein levels by Western blot, and cytokine release by ELISA.

Results: In vivo , after 30 weeks of SC, PACAP -/- /ApoE -/- mice showed increased lumen stenosis compared with ApoE -/- mice. In atherosclerotic plaques of PACAP -/- /ApoE -/- mice under CED, immunoreactive areas of VPAC1, CD86, and CD163 were increased compared with ApoE -/- mice. In vitro , VPAC1 protein levels were increased in PACAP -/- /ApoE -/- BMDM compared with ApoE -/- BMDM, resulting in increased TNF-α mRNA expression in BMDM1-MΦ and decreased TNF-α release in BMDM2-MΦ. Concerning lipid homeostasis, PACAP deficiency decreased the area of lipid droplets in BMDM1-/M2-MΦ with concomitant increasing adipose differentiation-related protein level. In THP-1 M1-/M2-MΦ, the VPAC1 antagonist increased the uptake of oxLDL, whereas the VPAC1 agonist decreased the oxLDL-induced intracellular triglyceride content.

Conclusion: Our data suggest that PACAP via VPAC1 signaling plays an important regulatory role in inflammatory processes in atherosclerotic plaques and in lipid homeostasis in different MΦ-subtypes, thereby affecting foam cell formation. Therefore, VPAC1 agonists or PACAP may represent a new class of anti-atherogenic therapeutics.

Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

(© 2023 Witzel, Block, Pollmann, Oetzel, Fleck, Bonaterra, Kinscherf and Schwarz.)

Titel:
PACAP regulates VPAC1 expression, inflammatory processes and lipid homeostasis in M1- and M2-macrophages.
Autor/in / Beteiligte Person: Witzel, R ; Block, A ; Pollmann, S ; Oetzel, L ; Fleck, F ; Bonaterra, GA ; Kinscherf, R ; Schwarz, A
Link:
Zeitschrift: Frontiers in cardiovascular medicine, Jg. 10 (2023-10-13), S. 1264901
Veröffentlichung: Lausanne : Frontiers Media S.A., [2014]-, 2023
Medientyp: academicJournal
ISSN: 2297-055X (print)
DOI: 10.3389/fcvm.2023.1264901
Sonstiges:
  • Nachgewiesen in: MEDLINE
  • Sprachen: English
  • Publication Type: Journal Article
  • Language: English
  • [Front Cardiovasc Med] 2023 Oct 13; Vol. 10, pp. 1264901. <i>Date of Electronic Publication: </i>2023 Oct 13 (<i>Print Publication: </i>2023).
  • References: J Biol Chem. 1998 Nov 20;273(47):31427-36. (PMID: 9813054) ; Annu Rev Biochem. 2012;81:687-714. (PMID: 22524315) ; J Mol Med (Berl). 2017 Nov;95(11):1153-1165. (PMID: 28785870) ; PLoS One. 2010 Jan 25;5(1):e8852. (PMID: 20111605) ; Mol Immunol. 2013 Mar;53(3):179-86. (PMID: 22944456) ; Exp Mol Pathol. 1990 Jun;52(3):300-8. (PMID: 2369935) ; Front Immunol. 2014 Sep 02;5:420. (PMID: 25228902) ; Pharmacol Ther. 2009 Mar;121(3):294-316. (PMID: 19109992) ; Br J Pharmacol. 2012 May;166(1):4-17. (PMID: 22289055) ; FASEB J. 1997 Dec;11(14):1317-28. (PMID: 9409551) ; Regul Pept. 1985 Oct;12(2):145-53. (PMID: 2999883) ; Biochem Biophys Res Commun. 2014 Nov 28;454(4):524-30. (PMID: 25450687) ; J Biol Chem. 2000 Dec 1;275(48):37324-32. (PMID: 10973959) ; Atherosclerosis. 2019 Feb;281:128-136. (PMID: 30658188) ; Endocrinology. 1994 Dec;135(6):2662-80. (PMID: 7988457) ; Atherosclerosis. 2011 Feb;214(2):345-9. (PMID: 21167486) ; Biochim Biophys Acta. 2008 Sep;1783(9):1663-72. (PMID: 18435935) ; J Neuroimmunol. 1996 Aug;68(1-2):27-38. (PMID: 8784257) ; J Stroke Cerebrovasc Dis. 2013 Oct;22(7):910-8. (PMID: 23273713) ; Arterioscler Thromb Vasc Biol. 2006 Aug;26(8):1702-11. (PMID: 16728653) ; BMC Mol Biol. 2009 Jul 02;10:66. (PMID: 19573231) ; Immunobiology. 2019 Jan;224(1):124-132. (PMID: 30447883) ; Mol Immunol. 2010 Apr;47(7-8):1650-60. (PMID: 20299103) ; Proc Natl Acad Sci U S A. 2002 Jan 8;99(1):461-6. (PMID: 11756684) ; F1000Prime Rep. 2014 Mar 03;6:13. (PMID: 24669294) ; J Neuroimmunol. 1998 May 15;85(2):155-67. (PMID: 9630164) ; Immunol Rev. 2014 Nov;262(1):153-66. (PMID: 25319333) ; Biochem Biophys Res Commun. 1989 Oct 16;164(1):567-74. (PMID: 2803320) ; Pharmacol Rev. 2000 Jun;52(2):269-324. (PMID: 10835102) ; J Leukoc Biol. 1998 May;63(5):591-601. (PMID: 9581803) ; J Biol Chem. 1993 Jun 5;268(16):11811-6. (PMID: 7685021) ; Br J Pharmacol. 2012 May;166(1):42-50. (PMID: 21951273) ; Int J Cancer. 1980 Aug;26(2):171-6. (PMID: 6970727) ; Mol Pharmacol. 2006 Jan;69(1):363-73. (PMID: 16244179) ; J Exp Med. 1992 Jul 1;176(1):287-92. (PMID: 1613462) ; Arterioscler Thromb Vasc Biol. 2009 Oct;29(10):1419-23. (PMID: 19696407) ; J Clin Invest. 2005 Aug;115(8):2192-201. (PMID: 16075060) ; Scand J Immunol. 2008 May;67(5):453-63. (PMID: 18405323) ; FEBS J. 2006 Aug;273(15):3498-510. (PMID: 16884492) ; Front Immunol. 2014 Nov 12;5:579. (PMID: 25429291) ; Nat Methods. 2012 Jun 28;9(7):676-82. (PMID: 22743772) ; Arterioscler Thromb Vasc Biol. 2013 Jun;33(6):1120-6. (PMID: 23640492) ; N Engl J Med. 1999 Jan 14;340(2):115-26. (PMID: 9887164) ; J Biol Chem. 2018 Jul 20;293(29):11415-11423. (PMID: 29871928) ; Front Mol Biosci. 2021 May 07;8:679797. (PMID: 34026849) ; Arterioscler Thromb Vasc Biol. 2004 Mar;24(3):504-10. (PMID: 14707038) ; J Immunol. 2006 Nov 15;177(10):7303-11. (PMID: 17082649) ; J Immunol. 2018 Jun 1;200(11):3697-3710. (PMID: 29669783) ; Am J Respir Cell Mol Biol. 2015 Nov;53(5):676-88. (PMID: 25870903) ; Endocr Rev. 2000 Dec;21(6):619-70. (PMID: 11133067) ; Nature. 2014 Mar 13;507(7491):238-42. (PMID: 24487620) ; J Biol Chem. 2001 Jan 5;276(1):369-80. (PMID: 11029467) ; Cell. 2011 Apr 29;145(3):341-55. (PMID: 21529710) ; Ann N Y Acad Sci. 2006 Jul;1070:1-628. (PMID: 16991209) ; Front Cardiovasc Med. 2018 May 11;5:32. (PMID: 29868610) ; J Biol Chem. 1987 Mar 15;262(8):3603-8. (PMID: 3102491) ; Atherosclerosis. 2012 Dec;225(2):461-8. (PMID: 23078881) ; Med Sci Monit Basic Res. 2017 Jun 15;23:240-249. (PMID: 28615615) ; Front Endocrinol (Lausanne). 2019 Oct 22;10:729. (PMID: 31695683) ; J Pharmacol Sci. 2008 May;107(1):41-8. (PMID: 18446003) ; Methods Mol Biol. 1998;108:119-30. (PMID: 9921522) ; Eur J Immunol. 2017 May;47(5):765-779. (PMID: 28393361) ; Regul Pept. 2002 Oct 15;108(2-3):165-73. (PMID: 12220741) ; J Immunol. 1999 Jan 15;162(2):1200-5. (PMID: 9916753) ; Mol Endocrinol. 2001 Oct;15(10):1739-47. (PMID: 11579206) ; J Vis Exp. 2016 Apr 14;(110):. (PMID: 27168390) ; J Mol Med (Berl). 2002 Jan;80(1):16-24. (PMID: 11862320) ; Vascul Pharmacol. 2004 May-Jun;41(4-5):139-46. (PMID: 15607497) ; J Biol Chem. 1996 May 17;271(20):11798-805. (PMID: 8662601) ; Ann N Y Acad Sci. 1999;897:401-14. (PMID: 10676466) ; Biochem Biophys Res Commun. 1994 Apr 29;200(2):769-76. (PMID: 8179610) ; Oncotarget. 2017 Jun 27;8(26):42728-42741. (PMID: 28473666) ; Curr Drug Targets. 2012 Jan;13(1):103-15. (PMID: 21777182) ; J Mol Neurosci. 2018 Sep;66(1):102-113. (PMID: 30105629) ; Curr Pharm Des. 2001 Jan;7(2):89-111. (PMID: 11172702) ; Sci Rep. 2019 May 14;9(1):7383. (PMID: 31089161) ; Trends Cardiovasc Med. 2001 Jan;11(1):22-5. (PMID: 11413048) ; Circ Res. 2011 Jan 21;108(2):235-48. (PMID: 21252151) ; Biochem Biophys Res Commun. 2010 Nov 19;402(3):471-6. (PMID: 20951679) ; Curr Opin Lipidol. 2010 Aug;21(4):305-11. (PMID: 20531184) ; Peptides. 2010 Nov;31(11):2035-45. (PMID: 20691743) ; Am J Physiol. 1994 Sep;267(3 Pt 1):L256-62. (PMID: 7943252)
  • Contributed Indexing: Keywords: PACAP; VPAC1; atherosclerosis; inflammation; macrophages; oxLDL
  • Entry Date(s): Date Created: 20231030 Latest Revision: 20231031
  • Update Code: 20240513
  • PubMed Central ID: PMC10611464

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

oder
oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

oder
oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.

xs 0 - 576
sm 576 - 768
md 768 - 992
lg 992 - 1200
xl 1200 - 1366
xxl 1366 -